Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Mesothelioma 21Mesothelioma, Malignant 18Advanced Solid Tumor 17Carcinoma, Non-Small-Cell Lung 15Solid Tumor 14Advanced Solid Tumors 13Melanoma 12Esophageal Neoplasms 10Carcinoma, Renal Cell 10Stomach Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Uterine Cervical Neoplasms 8Solid Tumors 8Ovarian Neoplasms 8Solid Tumor, Adult 7Neoplasm Metastasis 7Colorectal Neoplasms 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 6Breast Neoplasms 6Pancreatic Neoplasms 5Lung Neoplasms 5Endometrial Neoplasms 5Cholangiocarcinoma 5Neoplasms 4Locally Advanced or Metastatic Solid Tumors 4Head and Neck Neoplasms 4Advanced or Metastatic Solid Tumors 4Urinary Bladder Neoplasms 3Solid Tumor Malignancies 3

Interventions

pembrolizumab 3vadimezan 1malic acid 1Valproic Acid 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Solid Tumor Malignancies × pembrolizumab × Other solid neoplasm × Clear all
NCT06960395 2026-04-13

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Vir Biotechnology, Inc.

Phase 1 Recruiting
450 enrolled
Other solid neoplasm

Solid Tumor Malignancies

NCT06994806 2026-03-03

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Kumquat Biosciences Inc.

Phase 1 Recruiting
84 enrolled
Other solid neoplasm

Solid Tumor Malignancies

NCT07174453 2025-12-08

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

University of Kansas Medical Center

Phase 3 Recruiting
192 enrolled
Other solid neoplasm

Solid Tumor Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡